BSX
Watchman is getting the side-eye
Truist took a tiny scalpels-to-the-target move on Boston Scientific, cutting its price target to $90 from $92 while keeping a Buy rating intact. So no, this isn’t a full-blown “run for the exits” moment — more like a nervous glance at the growth runway.
The Watchman wrinkle
The firm’s main concern is Watchman momentum. Truist thinks the CLOSURE-AF impact may have slowed first-quarter growth more than the street — and management — expected. It now models Watchman growth of 18% year over year, below consensus around 22%.
That matters because when one of your key products starts wobbling, investors start asking the annoying but fair question: is this a hiccup, or the first crack in the windshield?
Guidance-watch season
Truist also said investors are bracing for management to potentially trim 2026 organic revenue guidance from the current 10% to 11% range down to something closer to 8% or higher. That’s not exactly the kind of phrase that makes people pour celebratory coffee.
On the flip side, the firm pointed to March 2026 CHAMPION trial results as a possible offset later on. Translation: there’s still a catalyst on the calendar, and Boston Scientific doesn’t have to live and die by Watchman alone.
Big picture: the call is still constructive, but the tone shifted from “smooth sailing” to “watch the currents.” For investors, the stock’s near its 52-week low, so even small changes in growth expectations can move the mood fast.